Pan-African Journal of Health And Psychological Sciences
ISSN: 3093-4737 | www.pajhps.org
Vol.2, Issue 2 | April-June 2026

Depression Unveiled: Current Understanding and Pathways to Recovery

Author(s): [1]Gagandeep Singh, [2]Imanshu, [3]Ruhit Ashraf *,[2]Shafkat Hussain Malik, [2]Sheikh Irshad Ul Haq

[1]B. Pharmacy (Student), School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab, India.

[2] Assistant Professor, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab, India.

[3] Associate Professor, S. Lal Singh Memorial College of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab, India.

Corresponding Author:

Ruhit Ashraf
Associate Professor
Email: ruwaidashraf1819@gmail.com

Abstract

Depression is a complex mental illness and one of the largest global public health issues which impacts over 280 million people worldwide. It is predetermined with the constant low mood, absence of pleasure (anhedonia), impaired thinking and dysfunction, and it is the result of the complicated interplay of genetic and biological, psychological and environmental factors. Depression theories date back to humoral melancholia ideas and were transformed in relation to earlier psychoanalytic interpretations to the modern biopsychosocial and neurobiological model. The studies of the present day accentuate structural and functional dysfunctions of principal brain areas, impairments of neurotransmitter networks, adaptive stress reactions, and neuroinflammation as the main factors of the origins of depression. Poverty, discrimination, low levels of education, and poor access to healthcare are all social determinants that make people

Singh, G. et al. (2026) **Depression Unveiled: Current Understanding and Pathways to Recovery. Pan-African Journal of Health and Psychological Sciences. Vol 2; Issue 2. April-June 2026. https://doi.org/10.64261/vjtak127.**

ISSN: 3093-4737

even more vulnerable and slow down their recovery process. Pharmacotherapy, psychotherapeutic modalities, and lifestyle modification are evidence-based interventions, whereas neuromodulation therapies, including electroconvulsive therapy and transcranial magnetic stimulation, are also effective interventions in people with treatment-resistant depression. New therapies, such as ketamine-based therapies, anti-inflammatory, and precision care based on pharmacogenetic are emerging to provide new avenues to quick and specific symptom treatment. Integrated management is needed in the form of long-term recovery, which facilitates psychosocial support, resilience, reintegration into the community, and functional restoration. The future of the world in the diagnostics and treatment of depression has a high potential due to advancements in neuroscience, personalized medicine, and digital therapeutics, which can bring more specific, effective, and available treatment.

Keywords: Depression, Neurobiology, Risk Factors, Diagnosis, Neuroimaging, Psychotherapy

1. Introduction

Depression is a disastrous mental condition, which is complex and multifactorial, and forms a crucial worldwide population health issue(1). According to World Health Organization, it is divinely characterized by persistent low mood, loss of interest, or pleasure, intellectual deficits, and functional dysfunction and on top of it all it impacts over 280 million people across the world(2).It is caused by an intricate combination of genetic, biological, psychologic and environmental factors, which makes the process of its accurate diagnosis and effective treatment especially difficult(3). Research has over the past decades attempted to explain the pathophysiology of depression, improve testing procedures as well as formulate more effective therapeutic interventions(4).Major mental health concern in the older adult population is depression which is often underestimated(5). However, later life depression is managed. The interventions that have evidence-based practices include psychotherapy (e.g., cognitive-behavioral therapy), pharmacotherapy (using antidepressants), lifestyle changes, and strong social support networks(6). Early diagnosis and personalized treatment are the key to better results of elderly people with depression. On top of personal impairment, depression

ISSN: 3093-4737

is a significant factor in lowering the quality of life, disrupting normal functioning, and increasing the morbidity of other comorbid conditions like cardiovascular disease, diabetes and chronic pain. It is a disorder that is highly associated with suicide that kills over 700,000 people every year, making it one of the leading causes of mortality among young people in the 1529 years group. Depression also leads to economic losses in the global economy since it is estimated by the world economic forum that mental health problems, including depression may consume up to 16 trillion dollars of the global economy by the year 2030 unless efforts are put up to reduce these issues(7). Although it is a common and drastic condition, depression is undiagnosed and untreated, especially in low-income and middle-income nations where mental health services are limited due to financial limitations. A multi-layered approach including the initiatives of public health, education, adoption of mental health as a part of primary care, and investment in mental health services is a solution to reducing the global effects of depression(8). This review is intended to give a holistic perspective of depression by analyzing its complex nature in terms of epidemiology, risk factors, clinical presentation, biological processes accompanying it, and its modern treatment. Due to the miscellaneous and international importance of the depression phenomenon, the article aims at the synthesis of the existing research to provide a contribution to the latest changes and the current issues in the direction(9).

2. Historical Perspectives

2.1. Development of the Concept Depression

Knowledge about depression has greatly developed throughout centuries with the changes in medical knowledge, attitude in cultures and scientific developments. Philosophically or religiously, depression used to be understood historically(10). Hippocrates in the antiquity described a disorder known as melancholia, which occurred due to the unbalance of body humors, especially the excess of black bile. This was a humoral theory that ruled the medical thought of centuries, equating emotional disturbances to the physical imbalance(11). Depression in the Middle Ages and the Renaissance period was often considered a spiritual or

ISSN: 3093-4737

moral weakness, with some people blaming it on demonic infestation or sin. Depression started to be considered as a particular mental disorder as psychiatry appeared in the eighteenth and nineteenth centuries. The classification of mood disorders Early psychiatrists like Emil Kraepelin, discriminated between manic and depressive moods. The twentieth century was characterized by significant changes as psychoanalytic theories were developed by Sigmund Freud who viewed depression as the conflict and loss which were not on the surface(12). Biological psychiatry developed further and investigated the neurotransmitters and brain pathways, as a result of which the contemporary biopsychosocial model was established. This is a combination of genetic, neurochemical, psychological, and environmental variables, and this is because depression is a multifactorial disorder(13). Depression is now understood as one of the complicated and heterogeneous disorders exhibiting different manifestations. The conceptualisation of the technology is still under development with improvements in neuroimaging, genetics and psychopharmacology to make it easier to diagnose and provide treatment. The concept of depression has evolved and this is part of the trend which has seen mental health being viewed as a combination of mind, body and environment(14).

2.2 Change in Diagnostic and Therapeutic Processes

Diagnostic Methods: Clinical observation and the subjective report of a patient depended mainly on the early diagnosis of depression. The formulation of a set of diagnostic criteria to be used in the twentieth century transformed the field(15). With the release of Diagnostic and Statistical Manual of Mental Disorders (DSM), which was by the American Psychiatric Association, it was possible to have clear operationalised criteria about major depressive disorder (MDD) and other mood disorders. The consecutive versions of the DSM (since DSM-III) enhanced better reliability and consistency during diagnosis to support research and treatment. Simultaneously, the World Health Organization, the International Classification of Diseases (ICD) offered the world with standards of diagnosis in different countries as well. Scales and questionnaires (e.g., Hamilton Depression Rating Scale, Beck Depression Inventory) have

ISSN: 3093-4737

been integrated in the diagnostic tools more recently to measure the severity when deploying them to assess and track treatment responses. New biomarkers and neuroimaging

methods are under investigation to offer objective measures but these are also secondary methods and not the main ones(16).

3. Etiology and Risk Factors

3.1 Genetic and Biological Influences

Depression has been well established as a complicated condition which occurs as a product of genetic, biological and environmental influences. Genetic studies such as family, twin and adoption research, have repeatedly shown a genetic aspect of depression and their estimation showed that the risk is almost thirty to forty percent inheritable by genetic element(17). Although there is no single genome depression gene due to its polygenic nature, specific protein variations of the neurotransmitter systems have been associated with it including serotonin, dopamine, and norepinephrine systems(18). Depression on a biological level is the change in the structure and functioning of the brain. Brain scans have actually depicted alterations in brain regions that deal with mood, such as the pre-frontal cortex, hippocampus and amygdala. Such areas tend to be smaller or less active in depressed people that is likely to be associated with such symptoms as the loss of emotional control and memory(18). Central pathophysiology of depression is related to neurochemical abnormalities and especially with serotonin, norepinephrine and dopamine. The monoamine hypothesis holds that the levels of these neurotransmitters are low (or they become low) in contributes to the symptoms of depression, which is the foundation of most antidepressant drug classes(19). Also, chronic stress and depression have been attributed to dysregulation of hypothalamic-pituitary-adrenal (HPA) axis that controls the stress response of the body. Although the mechanisms involved in inflammatory responses and immune imbalance are not clearly understood, this is an emerging area of research, and aggregate inflammation through the body system could contribute to causes of depression in certain instances(20). Moreover, epigenetic processes - modifications in

ISSN: 3093-4737

gene expression in the absence of genetic changes - underscore the fact that environmental factors that cause changes in biological susceptibility (trauma or stress) can alter gene expression. In short, genetic and biological factors constitute a well-established element of the etiology of depression, providing a decisive insight into the process of depression and informing the construction of specific treatment(21).

3.2 Psychological and Environmental provocateurs



Figure 1: Specific brain regions and neural circuits involved in psychological and environmental factors related to depression

A complicated interplay of psychological antagonisms and the environment leads to depression. Depression may also be predisposed by psychological factors like the personality

ISSN: 3093-4737

traits, cognitive patterns and childhood experiences(22). To illustrate, persons who have negative thinking tendencies, low self-esteem or maladaptive coping are at greater risk. Learned depression in the later life may be influenced by early childhood trauma, abuse, neglect or loss, which leave a permanent emotional scar. The presence of environmental triggers is also instrumental in the disturbance of the depressive episodes as well as in their recurrence(23). These may be stressful life situations, as the death of the person one loves, divorce, financial or job losses, or any external factor that leaves a person unable to handle it. The state of depression is also developed because of the chronic stressors that occur particularly in relation conflict, social isolation or exposure to violence(24). There exists the effect of social support and environmental context. Good social networks and supportive relations can be of help in alleviating depressions, whereas loneliness and rejection make a person susceptible. Some of the socioeconomic issues that increase risk include poverty, unemployment and inability to access healthcare(25).

3.3 Social Determinants of Mental Health

Social determinants influence the concept of mental health, including depression, in an absolute way: that is, conditions, which exist at the time of birth, throughout development, in the surrounding environments, in work place, and lifespan, are the determinants of mental health, including depression. Such determinants break or regulate the vulnerability of a person to mental health issues and determine their availability to care and recovery pathways(26).

The relevant social determinants affecting depression are:

- **Socioeconomic Status (SES):** Low income, poverty, and unemployment have a strong relationship with the high levels of depression. Economic hardship may trigger episodes of chronic stress, reduce access to health-care services, undermine the intake of nutritional products, and limit social interaction, thus, adding to the issue of mental health(27).

ISSN: 3093-4737

- **Education:** The less the schooling levels, the higher the risk of depression. The level of education enlightens health literacy, the possibility of getting a job, and social mobility, which together influence the mental health(28).
- **Housing and Neighbourhood:** Stress is aggravated by the adverse housing conditions, overcrowding, unsafe neighbourhood, and residential instability which undermine the social cohesiveness and thus increase the risk of depression(29).
- **Accommodating Factors:** Strong Social Networks and Community. Social isolation, discrimination, and marginalization on the contrary, aggravate the loneliness and depressive symptomatology(30).
- **Employment Conditions**: Greater prevalence of depression is related to job insecurity, work stress and lack of control over work activities. On the other hand, meaningful employment and helpful organizational climate lead to psychological well-being(30).
- **Healthcare:** Inequality Few people can receive timely and effective mental-health care due to disparities in access to these services, cultural attitudes, and stigma(31).
- **Discrimination and Social Inequality:** Racism, sexism, and similar discriminatory experiences are a source of chronic stress and result in mental-health disparities(32).

These social determinants need to be addressed to support the mental health promotion and the reduction of global burden of depression. Such policies as those promoting social equity, reduce poverty, enhance education access and build inclusive communities can have significant positive influences on mental health(33).

4. Neurobiological Mechanisms

4.1 Systems and Brain Regions Involved Neurotransmitter

Depression is a complex psychiatric illness, which is defined by the constant low mood, anhedonia, cognitive impairment, and somatic discomfort. The elucidation of the neuro biological basis of depression requires an elaborate analysis of the key neuromodulatory mechanisms as well as neuromodulators involved in the pathophysiology of depression(34).

ISSN: 3093-4737

4.1.1 Depression and the Systems of Neurotransmitters

Serotonin (5 -HT): Serotonin is a substance that is essential in maintenance of mood, anxiety, sleep, and appetite. The problem with serotonergic signaling is known to dysregulate depressive states, whether through the reduced synthesis or release or reduced receptor sensitivity(35). The key origin of the serotonergic neurons that project onto the prefrontal cortex, hippocampus, and limbic regions in the brainstem is the raphe nuclei hence influencing affective processing. The most commonly prescribed type of antidepressants called selective serotonin reuptake inhibitors (SSRI) improves the access of serotonin in the synaptic cleft and acts in a way that eases mood and anxiety symptoms(36).

Norepinephrine (NE): Norepinephrine helps in arousal, alertness as well as the physiological stress reaction. Abnormal noradrenergic mechanisms also have the potential of stimulating depression-related symptoms like fatigue, decreased concentration, and retardation of psychomotor functions. Locus coeruleus, a center of norepinephrine production located in the brainstem, is projected to most parts of the brain, including the prefrontal cortex, hippocampus, and other parts of the cortex. Serotonin-norepinephrine reuptake inhibitor (SNRI) and other agents are used to address this system to reduce presentations of depression(37).

Dopamine (DA): Dopamine controls motivation, reward processing as well as hedonic experience. The anhedonia, one of the cardinal symptoms of depression, which means the loss of the ability to derive pleasure, is associated with impaired dopaminergic transmission and specifically in the mesolimbic pathway (ventrals tegmental area to nucleus accumbens). The prefrontal cortex is also plagued with Dopaminergic dysfunction which can bring about cognitive impairments seen during the depressive illness(38).

Glutamate and GABA: Glutamate is the main excitatory neurotransmitter and GABA is the main inhibitory homologue. The two maintain the balance between excitation and inhibition of the nerves. There are gradual pieces of evidence to suggest that depressive symptomatology can be a result of

ISSN: 3093-4737

the perturbations of glutamatergic and GABAergic circuitry. Dysregulation of neural circuits can be facilitated by excess glutamate activity, or lack of GABA tone and it cause mood dis-regulation. Examples of therapeutic possibilities in this system include rapid-acting antidepressants like ketamine which, like glutamatergic receptors, promotes its action. (39)

4.1.2 Depression-Involved regions of the brain

Prefrontal Cortex (PFC): The PFC, especially, the dorsolateral and ventromedial portions of the area, lays a role in coordinating the executive functions, decision-making, and emotion(40). The depressive episodes incurred hypoactivity in the PFC, thus affects mental control of the negative cognitions and emotions, which leads to rumination and mood fluctuations(41).

Hippocampus: Hippocampus plays a vital role in learning, consolidation of memory and the control of stress. The pathology of depression has always shown itself through the decrease in hippocampal volume and impaired neurogenesis, presumably caused by chronic stress and high levels of cortisols. These structural changes correlate with the memory impairment and affective disorders(42).

Amygdala: The amygdala plays a vital role in processing the affective stimuli, in particular, fear and threat stimuli. Amygdala hyperactivity also helps to increase negative emotional processing and anxiety in depressed patients(43).

Anterior Cingulate Cortex (ACC): The ACC is involved with the emotional regulation and conflict monitoring. Ineffective ACC functioning is in line with poor affective regulation and selective attention biases to negative stimuli thereby exerting depressive symptom repair(44).

Nucleus Accumbens: Being a focal point of the reward circuitry, the nucleus accumbens is involved in mediating the motivation and hedonic pleasure. Spinal dysfunction of dopaminergic signaling combined in this field leads to anhedonia and loss of motivation typical of depression(45).

ISSN: 3093-4737

Hypothalamus: Hypothalamus controls the hypothalamic-pituitary-adrenal (HPA) axis thus regulating stress in the body. Hyperactivity of the HPA axis in depression predisposes excessive secretion of cortisol and can cause neuronal damage and additional interference with the regulation of mood(46).

4.2 Hormonal and Stress Response Pathways.

Depression is closely associated with the inability to regulate the hormonal and even stress-response mechanisms of the body, in particular, the HPA axis. Perturbed persons engage in a chain reaction where the hypothalamus secreted corticotropin-releasing hormone (CRH) which activated the pituitary gland to discharge adrenocorticotropic hormone (ACTH)(46). ACTH then stimulates the adrenal glands to synthesize cortisol which is the most essential glucocorticoid stress hormone(47). HPA axis hyperactivity in most depressed patients results in chronically high cortisol levels that cause neuronal damage, particularly in neurons in the hippocampus and consequently failure to regulate the stress response negatively(46). Prolonged cortisol elevation has pernicious impacts on other affective foci, such as the prefrontal cortex and amygdala, contributing to aggravation of pathology of depression(46).The disruption of moods that are regularly seen in depression is caused by perturbations in other endocrine systems including thyroid and sex hormones(48).

4.3 Unemerging Applications of neuroimaging

The recent developments in neuroimaging have significantly contributed to our understanding of neurobiological premises of depression(14). Such modalities as functional magnetic resonance imaging (fMRI), positron emission tomography (PET) and diffusion tensor imaging (DTI) have produced the most decisive findings about deviations in cerebral activity, interregional connections as well as the anatomy of persons with depressive disorders(49). A single observation that has been repeatedly replicated is that of dysregulated functioning and

ISSN: 3093-4737

connectivity of core neural networks medating affective state control, executive control as well as affective processing(50). As an example, the results of resting-state fMRI studies have reported impaired coherence in the default mode network (DMN), which is a circuitry closely connected with self-referential cognition and rumination which are hallmark characteristics of depressive pathology. Structural interferences of fronto-limbic networks such as a weakened activation of the prefrontal cortex (PFC) and over-responsive amygdalar activities have been repeatedly tested as a result of the failed emotional regulation and hypersensitivity to negative stimuli(51).

Volumetric imaging of the human brain has shown that grey-matter in the hippocampus, prefrontal cortex, and anterior cingulate cortex (ACC) are less developed, which is an event that is presumably reflective of the adverse effects of chronic stress and neurotoxicity(52). Microstructural abnormalities have been observed in white-matter tracts in DTI studies, indicating a dysfunction in communication between several key regions of corticolimbic and prefrontal tissue which are highly important in affective and cognitive processes(53). Moreover, imaging of monoaminergic neurotransmitter systems with the use of PET has demonstrated changes in serotonergic, dopaminergic and glutamatergic receptor occupancy in the depressed patient demonstrating direct evidence of neurochemical deregulation. These neuroimaging findings make it possible to create more personalized treatment interventions as neural activation patterns and connectivity profiles predict responsiveness to antidepressant therapy and inform individual neuromodulatory therapies (such as transcranial magnetic stimulation (TMS)(54).

ISSN: 3093-4737

Figure 2: Biological and environmental factors contributing to psychosis development

5. Clinical manifestation and Diagnosis

5.1 Diagnostic Criteria and Diagnostic Assessment Tools

Diagnostic diagnoses of the depression, especially the Major Depressive Disorder (MDD), are majorly based on the criteria that are defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Within these rules, to be diagnosed one must have a minimum of five symptoms that last at least two weeks, and one of which is either a depressed mood, or severe lack of interest or pleasure in almost everything (anhedonia)(55). Other requirements are a major change in either appetite or weight, sleeplessness (insomnia or hypersomnia), psychomotor agitation or retardation, fatigue or loss of energy, worthlessness or excessive guilt, impaired cognitive functioning (loss of concentration or decision-making), or frequent thoughts about death or suicide(56). These symptoms should cause significant distress or functional disability in any of the social, work or other areas and should not be better explained by effects of substances or other health condition or grief(57).

5.2 Subtypes and Comorbidities

ISSN: 3093-4737

Depression is a complex and heterogeneous psychopathology affecting individuals with different subtypes and having different clinical presentations and treatment implications(14). Some of the common subtypes include Major Depressive Disorder (MDD) with persistent and severe symptomatology, Persistent Depression Disorder (previously known as dysthymia) with chronic attenuated symptoms lasting years, melancholic depression (depressive who exhibit severe anhedonia and psychomotor changes), atypical depression, mood responsive, greater somatic appetite and sleep, and hypersensitive to interpersonal rejection; psychotic depression, (depressive who experience hallucinations or delusions), and seasonal affective disorder (SAD), with recurrent(58).

Most depressive disorders are always associated with other psychiatric illnesses like anxiety disorders, bipolar disorder, substance use disorders and post-traumatic stress disorder making it more difficult to diagnose, as well as to administer treatment. Moreover, the symptomatology of depressive disorders is usually overlaid on diverse ongoing somatic disorders, such as cardiovascular disease, diabetes mellitus, chronic pains syndrome, and neurodegenerative disease, and thereby, may make the courses of both psychiatric and medical disorder worse(59).

5.3 Problems with Differential Diagnosis

Diagnosing the major depression condition using the differentiated methods of assessment is a challenging task because symptoms are largely similar to those of other psychiatric and somatic diseases(60). Basic signs like poor mood, tiredness, and sleep disturbance are common to such disorders like bipolar disorder, anxiety disorders, and substance use disorders and make the distinction between the unipolar depression and those disorders conditional depending on exhaustive assessment. Certain medical conditions which include: hypothyroidism, nutritional deficiencies, neurological illness and chronic diseases can also imitate the symptomatology of depression further confusing the correct diagnosis solution(61).

ISSN: 3093-4737

The other complication is the inter-individual differences in presenting the symptoms depending on age, gender, and cultural differences which can mask or distort typical signs of depression(62). Comorbid conditions introduce further confounding variables, as they can cause depression symptoms to become more pronounced, or be sympathetically manifested, which requires laborious consideration of time, initiation, and contextuality(63). Further presence of subthreshold symptoms and overlapping affective disorders also necessitates the use of detailed clinical interviews and empirically-tested assessment tools to obtain a definite level of discrimination(64).

6. Existing Treatment Models

The modern treatment of the depressive disorders incorporates the use of pharmacological, psychotherapeutic and somatic treatment, which is tailored to the symptomatology, severity and type of depressive disorder of an individual(65).Pharmacotherapy mainly involves antidepressant drugs like selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), tricyclic antidepressants and atypical antidepressants; they work by regulating the system of neurotransmitters in order to reduce the symptoms of depression(66). The interventions of psychological approaches such as cognitive-behavioural therapy (CBT), interpersonal therapy (IPT), mindfulness-based cognitive therapy (MBCT) are focused on changing maladaptive thought process, solving interpersonal disagreement, and avoiding relapse by acquiring skills and modifying behaviour. In cases of treatment resistance or extreme depression, somatic modalities like electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS) can be used as alternative approaches since both of them have a direct impact on the neural activity(67). Behavioral changes such as physical exercise, sleep hygiene, and stronger psychosocial support are significant supplements that improve the general treatment effectiveness(68). New therapeutics that are directed at new neurochemical pathways, including ketamine and anti-inflammatory agents have received interest due to their ability to provide quick symptom improvement(69). Together, all these multidisciplinary methods allow individualized,

ISSN: 3093-4737

efficacious depression treatment by aiming to enhance clinical manifestations, reinstate functional functioning, and prevent recurrence(70).

Table 1: Justification of table and add serial no font style is in times new roman

Serial no.	Treatment Type	Examples / Approaches	Mechanism / Focus of Action	Clinical Application / Benefits	References
1.	Pharmacological Therapy	SSRIs (Fluoxetine, Sertraline), SNRIs (Venlafaxine, Duloxetine), TCAs (Amitriptyline), Atypical Antidepressants (Bupropion, Mirtazapine)	Regulate neurotransmitter systems (serotonin, norepinephrine, dopamine) to normalize mood and cognitive function	First-line treatment for moderate to severe depression; reduces mood and somatic symptoms	(71)
2.	Psychotherapeutic Interventions	Cognitive-Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Mindfulness-Based Cognitive Therapy (MBCT)	Modify maladaptive thought patterns, improve coping and problem-solving, reduce relapse risk	Effective for mild to moderate depression; often combined with medication for optimal results	(72)
3.	Somatic Treatments	Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS)	Direct modulation of brain activity to restore normal neuronal functioning	Used in severe or treatment-resistant depression; provides rapid symptomatic relief	(73)
4.	Behavioral and Lifestyle Modifications	Physical exercise, Sleep hygiene, Psychosocial support	Promote neuroplasticity, improve overall well-being, and	Supportive adjuncts to improve clinical	(74)

ISSN: 3093-4737

			enhance treatment adherence	outcomes and prevent relapse	
5.	Emerging / Novel Therapies	Ketamine, Ketamine, Anti-inflammatory agents	Act on glutamatergic and inflammatory pathways to induce rapid antidepressant effects	Beneficial in treatment-resistant cases; provide faster symptom improvement	(75)

6.1 Pharmacotherapy and Mechanisms of Action

Pharmacotherapy is a major aspect in the treatment of depression since it mostly involves the involvement of neurotransmitter systems involved in the regulation of mood(76). SSRIs, SNRI, tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs) and atypical are the antidepressants that are most commonly prescribed. An example of these is the selective inhibition of the serotonin (5 -HT) reuptake by SSRIs, such as fluoxetine and sertraline,

increasing its concentration in the synapses, and improving serotonergic transmission. SNRIs (e.g. venlafaxine and duloxetine) inhibit the uptake of serotonin and norepinephrine (NE) and enhance signaling in these pathways, thus enhancing affect and vitality(77). The TCAs prevent the reuptake of serotonin and norepinephrine and also affect other receptors of neurotransmitters, which also adds to the wider side-effect profile. MAOIs disrupt monoamine oxidase enzymes which process monoamines (serotonin, norepinephrine, dopamine) leading to an increase in the availability of neurotransmitters(78). The atypical antidepressants, which are bupropion and mirtazapine, act via different mechanisms, which include dopamine and norepinephrine reuptake inhibition or selective serotonin receptor modulation(71). Overall, these drug substances are normalizing the imbalance of important neurotransmitter systems that have been disturbed by depression, which improves mood,

ISSN: 3093-4737

cognition, and somatic symptoms(79). The explanations of these processes help clinicians to choose treatments that are in line with patient profile and tolerability issues(80).

Table 2: Justification of table and add serial no font style is in times new roman

Serial no.	Drug Class	Examples	Primary Mechanism of Action	Neurotransmitter (s) Affected	Clinical Effect / Notes	References
1.	Selective Serotonin Reuptake Inhibitors (SSRIs)	Fluoxetine, Sertraline	Inhibit reuptake of serotonin (5-HT) into presynaptic neurons, increasing synaptic serotonin levels	Serotonin (5-HT)	Improves mood and anxiety; first-line due to better tolerability	(81)
2.	Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)	Venlafaxine, Duloxetine	Block reuptake of both serotonin and norepinephrine	Serotonin (5-HT), Norepinephrine (NE)	Enhances mood, energy, and motivation; effective in fatigue-related depression	(82)
3.	Tricyclic Antidepressants (TCAs)	Amitriptyline, Imipramine	Inhibit reuptake of serotonin and norepinephrine; also act on histaminic, cholinergic, and adrenergic receptors	Serotonin (5-HT), Norepinephrine (NE), others	Effective but associated with more side effects (e.g., sedation, anticholinergic effects)	(71)
4.	Monoamine Oxidase Inhibitors (MAOIs)	Phenelzine, Tranylcypromine	Inhibit monoamine oxidase enzyme, preventing	Serotonin (5-HT), Norepinephrine (NE), Dopamine (DA)	Increases neurotransmitter availability; used for atypical or	(83)

ISSN: 3093-4737

			breakdown of serotonin, norepinephrine, and dopamine		treatment-resistant depression; dietary restrictions required	

6.2 Psychotherapy Modalities

The psychotherapy has a central role in depression treatment, and it has various empirically valid modalities, which address the interpersonal, cognitive, and emotional aspects of the disorder(84). One of the most commonly used methods is cognitive-behavioural therapy (CBT), which focuses on the detection and the change of the negative thought patterns and maladaptive behaviours that reinforce depressive conditions(85). Interpersonal therapy (IPT) is used to treat interpersonal conflicting situations, role change, and social-interpersonal deficits that often initiate and maintain depression, hence enhances relationship functioning(86). Mindfulness-based cognitive therapy (MBCT) involves using cognitive therapeutic methods with mindfulness training to promote an increased awareness of thoughts and feelings, as well as

acceptance of them, to limit the risk of a relapse(87). Other modalities like behavioural activation should be used to increase involvement in rewarding activities to overcome depressive withdrawal(88). The psychotherapeutic interventions can be implemented as a stand-alone measure, or they can be used along with pharmacotherapy, and provide the patient with the means to cope with the symptoms, improve coping capabilities, and ensure a long-lasting recovery(89).

6.3 Lifestyle and Behavioral Interventions

Behavioural and lifestyle intervention are essential supplements in managing depression that supplement pharmacological and psychotherapeutic therapies(76). Exercise has been shown to have enormous antidepressant effects due to its stimulation of neurogenesis, improvement

ISSN: 3093-4737

of the functions of neurotransmitters, and inhibition of inflammatory mechanisms(90). Moreover, the methods of managing stress such as mindfulness meditation, relaxation practices, and yoga help achieve better results in terms of stress-hormone levels and improvements in emotional resilience(91). Social support and psychoeducational programs are also very important as they reinforce coping skills and compliance with treatment(92). Combined, these lifestyle changes promote a holistic wellbeing and enhance the treatment outcome among patients diagnosed with depression(74).

7. Innovations in Treatment

The sphere of depression treatment is developing fast offering new opportunities to patients whose response to traditional therapies is weak(15). One of the most important developments has been the use of ketamine and its analogue esketamine which are known to mediate the glutamatergic system by antagonising the NMDA receptors, hence producing rapid antidepressant actions that are usually exhibited in hours, which is a significant improvement over traditional antidepressants, which take several weeks to show any effect(93). Simultaneously, studies on the impact of inflammation and maladaptive regulation of immune system on the pathology of depression have provided opportunities to consider the use of anti-inflammatory agents as the add-on treatment(94). Advances in personalise medicine, such as genetic testing, help clinicians to make interventions specific to the biological and genetic characteristics of different individuals(95).These new approaches to treatment indicate a growing understanding of the multifaceted neurobiology of depression and are transforming the treatment paradigm into a better patient outcome(96).

7.1 The therapies include neuromodulation and brain stimulation therapies

Neuromodulation and brain stimulation treatment has become prospective effective therapeutic modalities amongst depressed patients especially those who have developed resistance to alternative pharmacologic and psychotherapeutic treatments(97). Despite its effectiveness that has been adequately described, ECT is often limited by cognitive side effects and

ISSN: 3093-4737

stigma in society. The more recent and non-invasive methods like Transcranial Magnetic Stimulation (TMS) use magnetic fields to target particular brain structures- usually the left dorsolateral prefrontal cortex - to alter the brain activity and enhance mood regulation, and have a better side-effect profile than ECT(98). Transcranial Direct Current Stimulation is another upcoming form; it is a form of electrical current that applies low-intensity currents to specific regions of the cortex to alter neuronal excitability(99). Extreme refractoriness In severe refractoriness, Deep Brain Stimulation (DBS) is surgery in which electrodes are implanted to stimulate the circuitry involved in affective disorders; it is currently in its infancy. These neuromodulation strategies offer special treatments that can alter the maladaptive neural circuits and thus form an important addition to patients whose depressive symptoms have remained inactive and hence broaden the therapeutic scope of the current therapeutic options(100).

7.2 Genetic and Personalized Medicine

Genetic and personalized medicine is a new horizon in treatment of depression, and it seeks to individualize interventions basing on the unique genetic make-up, environmental exposure and biological markers of an individual(101). Studies have found out that many genetic variation types contribute to depression vulnerability, reaction to antidepressant drugs and a possibility of adverse effects(102). Pharmacogenetic tests assesses genes that deal with drug metabolism (e.g. CYP450 enzymes) and neurotransmitter processes to determine which drugs are most likely to be the most effective and well-tolerated by a specific patient(103). The up-to-one approach minimizes the trial and error approach that is common in antidepressant choice, and the approach could be more effective and quicker in alleviating symptoms(89). In addition to genetics, personalized medicine incorporates biomarkers, results of neuroimaging, and the history of the patient to create complete profiles that are used to determine the type of treatment to use(104).Genetic and personalized medicine is proving to have immense potential though it is still new to the day-to-day clinical practice and can be used to enhance the results and reduce adverse effects(105).

ISSN: 3093-4737

7.3 Digital and Telehealth Solutions

The digital and telehealth solutions are revolutionizing health care delivery through the use of technology to deliver remote, efficient, and patient-centered care(106). One of the key elements of digital health is telehealth, using which real-time or asynchronous communication between patients and health care providers can be arranged through video conferences, remote monitoring, and mobile communication(107).These solutions facilitate access to care especially in rural or underserved areas, reduce the workload on healthcare institutions and provide greater convenience to the patients and providers(108). There are still challenges like differences in digital access, privacy issues, regulatory challenges, and other issues; however, digital and telehealth technologies remain a central figure in the process of transforming healthcare systems and enhancing health outcomes(109).

8. Rehabilitation and Recovery

Recovery and rehabilitation are part and parcel of the healthcare continuum and it focuses on healing the physical, mental, and emotional strength of a person after a disease or injury or even after surgery(110). The first one is recovery, which implies the formation of the first stage of healing where patients obtain the necessary stabilization and start gathering the functional capacities; the second one is rehabilitation, which is the provision of organization therapies and assistance to restore mobility, independence, and quality of life(111). Such interventions can be physical therapy, occupational therapy, speech-language pathology, and psychological support, depending on the needs of the person(112). Good recovery and rehabilitation do not only save time; it is also effective in reducing risks of complications, hospital readmission as well as long-term well-being(113).These services can be delivered in hospitals, specialized rehabilitation facilities or the community based and online support programs at home(114).

8.1 Community Integration and Psychosocial Support

ISSN: 3093-4737

Having psychosocial support and integration into the community is also part of the holistic care and particularly of those who are recovering after sickness, trauma or are living with a chronic or disability(115). Psychosocial support is a way of meeting the emotional, social and psychological demands which help to cope with stress, anxiety, depression and adapting to changes in life(116). This assistance comes through the services of mental health specialists, peer support groups, family, or community organizations. The purpose of community integration is to reintegrate the persons into the society through encouraging them to participate in the social life, live independently, have access to education or job opportunities and by fostering a sense of belonging. Psychosocial support and community integration improve the overall well-being, reduce stigma and isolation and help people to live fulfilling, meaningful lives in their communities(117).

8.2 Factors that Support Recovery in the Long-Term

Long-term recovery factor is not only limited to immediate medical treatments but can be a wide range of emotional, social, and practical factors, which help a person to recover and readjust to normal daily living(118). The core of long-term recovery is frequent access to quality healthcare services and rehabilitation that underlies physical recovery and functional autonomy. Recovery is a process that also relies heavily on psychological strength; emotional support that can be gathered through counseling, therapy and peer networks can help people process and cope with stress or anxiety and build confidence back after an illness or trauma(119). The support system, a family of friends, and friends of community who offer motivation, companionship and practical help makes a big burden on recovery and offers a great relief to the victims(120). Additionally, there is the role of education and self-management, wherein the better people understand their condition and have means of dealing with it, the higher the chances of staying dedicated to their recovery path(121). Socioeconomic stability (such as stable housing, adequate finances, healthy eating, and work) establishes conditions which allow recovery without the stressors of survival(122). Social participation and involvement in the community make people feel important and unisolated, alleviating

ISSN: 3093-4737

isolation and promoting normalcy(123). In modern settings, digital and telehealth technologies help to supplement long-term recovery through continuous monitoring, virtual assistance, and accessible care across the geographical boundaries(124).

9. Future Directions

Depression is among the most debilitating and major mental illnesses today across the globe. In the World Health Organization, it is observed that over 280 million people are affected with depression with evidence of increasing prevalence rates due to social, economic and environmental pressures. In spite of the fact that the concept of depression has changed throughout the decades, the concept remains a multifactorial phenomenon that is complex in nature. The emergent studies already start to question the traditional assumptions and already offer the new directions in understanding, diagnosing, and treating depression in the future.The monoamine hypothesis has frequently been used as a traditional approach to depression, and this approach assumes that the disorder is caused by deficiencies in the neurotransmitters, including serotonin, norepinephrine and dopamine. However, recent research suggests that depression is not merely a biochemical imbalance the complex interaction between genetic, environmental, psychological, and neurobiological factors is instead involved. To illustrate, neuroinflammation, intolerance of the gut-brain axis, chronic psychosocial stress, and others, have all been involved in the pathogenesis of depression.

There is also the emergence of digital mental health technologies. Mental health care is being expanded by mobile applications, teletherapy systems, and systems powered by artificial intelligence and are providing real-time monitoring and intervention. Smartwatches and bracelets that measure the quality of sleep, physical activity, and even the tone of speech are experimented with in terms of timely warning a depressive episode.

The psychedelic-assisted therapy is undergoing a resurgence. Psilocybin, ketamine and MDMA are being studied as early and extensive antidepressants, particularly treatment recalcitrant depression. Laws governing these drugs are moving towards re-evaluation in

ISSN: 3093-4737

various countries worldwide as medical literature swells with evidence supporting the efficacy of the medicines.

The other area of study that is important is the gut-brain axis. Microbiome has been reported to affect the affective states and cognitive performance, and studies have shown that depressed people often have distorted gut flora composition. Adjunctive therapies to depression are also being considered as probiotic and prebiotic interventions as well as diet modification.

Conclusion

Depression has been an intricate and acute worldwide medical issue whose nature has been determined by a mutual reciprocal association of biological, psychological, and social factors. Although there have been tremendous advancements in comprehending its neurobiological pathophysiology, including neurotransmitter imbalance to neuroinflammation and stress-associated circuitry disruption, the disorder still manifests itself in a heterogeneous way, which makes it difficult to diagnose and provide individual treatment in time. The current clinical practice is based on evidence-based therapies, such as pharmacotherapy, psychotherapy, lifestyle modification, and neuromodulation. The fact that there are cases of treatment resistance, however, highlights the shortcomings of the traditional approaches and also emphasizes the necessity to be innovative. New treatment options including ketamine, anti-inflammatory drugs, and tailored medicine instructed by genetics present positive prospects of quicker and more specific treatment. Moreover, there is an improvement in digital mental health

services and community-based psychosocial services, which increase access and recovery in the long run. In the future, there is need to have a holistic, comprehensive model that considers neurobiological complexity as well as addressing social determinants. The further investigation, prevention and holistic rehabilitation approaches will be essential in the field of enhancing performance and decreasing the worldwide depression prevalence.

ISSN: 3093-4737

References

1. Adroa Afiya B. Interconnection between Depressive Disorders and Persistent Diseases. Res Invention J Res Med Sci. 2024;3(1):45-51.
2. Minas H. Depression in the developing world. Depression: Law and Ethics. 2017:186-98.
3. Weems CF, Carrion V, McCurdy B, Scozzafava MD. Increased risk of suicide due to economic and social impacts of social distancing measures to address the Covid-19 pandemic: A forecast. Res Prepr. 2020;9(926):10.13140.
4. Nemeroff CB. The state of our understanding of the pathophysiology and optimal treatment of depression: glass half full or half empty? American Journal of Psychiatry. 2020;177(8):671-85.
5. Brouwers EP. Social stigma is an underestimated contributing factor to unemployment in people with mental illness or mental health issues: position paper and future directions. BMC psychology. 2020;8(1):36.
6. Noetel M, Sanders T, Gallardo-Gómez D, Taylor P, del Pozo Cruz B, Van Den Hoek D, et al. Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials. bmj. 2024;384.
7. Chen XD, Li F, Zuo H, Zhu F. Trends in Prevalent Cases and Disability-Adjusted Life-Years of Depressive Disorders Worldwide: Findings From the Global Burden of Disease Study From 1990 to 2021. Depress Anxiety. 2025;2025:5553491.
8. Patel V, Araya R, Chatterjee S, Chisholm D, Cohen A, De Silva M, et al. Treatment and prevention of mental disorders in low-income and middle-income countries. The lancet. 2007;370(9591):991-1005.
9. Kouba BR, de Araujo Borba L, Borges de Souza P, Gil-Mohapel J, Rodrigues ALS. Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets. Cells. 2024;13(5):423.
10. Aggarwal S, Wright J, Morgan A, Patton G, Reavley N. Religiosity and spirituality in the prevention and management of depression and anxiety in young people: a systematic review and meta-analysis. BMC Psychiatry. 2023;23(1):729.
11. Pop M. Normal and abnormal and the body-soul relationship in some ancient medical texts. Balkan Journal of Philosophy. 2012;4(2):185-96.
12. Zivanovic O, Nedic A. Kraepelin's concept of manic-depressive insanity: One hundred years later. Journal of affective disorders. 2012;137(1-3):15-24.
13. Tripathi A, Das A, Kar SK. Biopsychosocial model in contemporary psychiatry: Current validity and future prospects. Indian journal of psychological medicine. 2019;41(6):582-5.
14. Buch AM, Liston C. Dissecting diagnostic heterogeneity in depression by integrating neuroimaging and genetics. Neuropsychopharmacology. 2021;46(1):156-75.
15. Stein DJ, Shoptaw SJ, Vigo DV, Lund C, Cuijpers P, Bantjes J, et al. Psychiatric diagnosis and treatment in the 21st century: paradigm shifts versus incremental integration. World Psychiatry. 2022;21(3):393-414.
16. EDITION F. Diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington, DC. 1980:205-24.

ISSN: 3093-4737

17. Lopizzo N, Bocchio Chiavetto L, Cattane N, Plazzotta G, Tarazi FI, Pariante CM, et al. Gene–environment interaction in major depression: focus on experience-dependent biological systems. Frontiers in psychiatry. 2015;6:68.
18. Nordquist N, Oreland L. Serotonin, genetic variability, behaviour, and psychiatric disorders-a review. Upsala journal of medical sciences. 2010;115(1):2-10.
19. Jiang Y, Zou D, Li Y, Gu S, Dong J, Ma X, et al. Monoamine neurotransmitters control basic emotions and affect major depressive disorders. Pharmaceuticals. 2022;15(10):1203.
20. Tsigos C, Chrousos GP. Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and stress. Journal of psychosomatic research. 2002;53(4):865-71.
21. Beck AT, Bredemeier K. A unified model of depression: Integrating clinical, cognitive, biological, and evolutionary perspectives. Clinical Psychological Science. 2016;4(4):596-619.
22. Beck AT. The evolution of the cognitive model of depression and its neurobiological correlates. American journal of psychiatry. 2008;165(8):969-77.
23. Saveanu RV, Nemeroff CB. Etiology of depression: genetic and environmental factors. Psychiatric clinics. 2012;35(1):51-71.
24. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychological bulletin. 2014;140(3):774.
25. Shi L, Stevens GD. Vulnerability and unmet health care needs: the influence of multiple risk factors. Journal of general internal medicine. 2005;20(2):148-54.
26. Minihan S, Orben A, Songco A, Fox E, Ladouceur CD, Mewton L, et al. Social determinants of mental health during a year of the COVID-19 pandemic. Dev Psychopathol. 2023;35(4):1701-13.
27. Ma J, Wu J, Marois G. Socioeconomic inequalities in depression and the role of job conditions in China. Front Public Health. 2024;12:1464187.
28. Ridley M, Rao G, Schilbach F, Patel V. Poverty, depression, and anxiety: Causal evidence and mechanisms. Science. 2020;370(6522):eaay0214.
29. Bonnefoy X. Inadequate housing and health: an overview. International journal of environment and pollution. 2007;30(3-4):411-29.
30. Brandt L, Liu S, Heim C, Heinz A. The effects of social isolation stress and discrimination on mental health. Translational psychiatry. 2022;12(1):398.
31. Thornicroft G. Stigma and discrimination limit access to mental health care. Epidemiology and Psychiatric Sciences. 2008;17(1):14-9.
32. Vargas SM, Huey Jr SJ, Miranda J. A critical review of current evidence on multiple types of discrimination and mental health. American Journal of Orthopsychiatry. 2020;90(3):374.
33. Kirkbride JB, Anglin DM, Colman I, Dykxhoorn J, Jones PB, Patalay P, et al. The social determinants of mental health and disorder: evidence, prevention and recommendations. World Psychiatry. 2024;23(1):58-90.
34. Dean J, Keshavan M. The neurobiology of depression: An integrated view. Asian journal of psychiatry. 2017;27:101-11.
35. Nihalani N, Simionescu M, Dunlop BW. Depression: phenomenology, epidemiology, and pathophysiology. Depression: CRC Press; 2009. p. 13-33.

ISSN: 3093-4737

36. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depression and anxiety. 2000;12(S1):2-19.
37. Liu Y, Zhao J, Guo W. Emotional roles of mono-aminergic neurotransmitters in major depressive disorder and anxiety disorders. Frontiers in psychology. 2018;9:2201.
38. Höflich A, Michenthaler P, Kasper S, Lanzenberger R. Circuit mechanisms of reward, anhedonia, and depression. International Journal of Neuropsychopharmacology. 2019;22(2):105-18.
39. Duman RS, Sanacora G, Krystal JH. Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron. 2019;102(1):75-90.
40. Hiser J, Koenigs M. The multifaceted role of the ventromedial prefrontal cortex in emotion, decision making, social cognition, and psychopathology. Biological psychiatry. 2018;83(8):638-47.
41. Gao W, Yan X, Yuan J. Neural correlations between cognitive deficits and emotion regulation strategies: understanding emotion dysregulation in depression from the perspective of cognitive control and cognitive biases. Psychoradiology. 2022;2(3):86-99.
42. Tartt AN, Mariani MB, Hen R, Mann JJ, Boldrini M. Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications. Mol Psychiatry. 2022;27(6):2689-99.
43. Adolphs R, Spezio M. Role of the amygdala in processing visual social stimuli. Progress in brain research. 2006;156:363-78.
44. Sheena MK, Jimmy J, Burkhouse KL, Klumpp H. Anterior cingulate cortex activity during attentional control corresponds with rumination in depression and social anxiety. Psychiatry Research: Neuroimaging. 2021;317:111385.
45. Taylor AM, Becker S, Schweinhardt P, Cahill C. Mesolimbic dopamine signaling in acute and chronic pain: implications for motivation, analgesia, and addiction. Pain. 2016;157(6):1194-8.
46. Sharan P, Vellapandian C. Hypothalamic-pituitary-adrenal (HPA) axis: Unveiling the potential mechanisms involved in stress-induced Alzheimer's disease and depression. Cureus. 2024;16(8).
47. Hasenmajer V, Bonaventura I, Minnetti M, Sada V, Sbardella E, Isidori AM. Non-canonical effects of ACTH: insights into adrenal insufficiency. Frontiers in Endocrinology. 2021;12:701263.
48. Bernardes BM, de Oliveira Borba MC, Moreira S, Sartori CS, da Silva Júnior IF, de Souza MTL, et al. Relationship between Mood Disorders and Thyroid Changes. Brazilian Journal of Implantology and Health Sciences. 2024;6(2):2241-56.
49. Babaeeghazvini P, Rueda-Delgado LM, Gooijers J, Swinnen SP, Daffertshofer A. Brain structural and functional connectivity: A review of combined works of diffusion magnetic resonance imaging and electro-encephalography. Frontiers in Human Neuroscience. 2021;15:721206.

ISSN: 3093-4737

50. Fournier JC, Bertocci M, Ladouceur CD, Bonar L, Monk K, Abdul-Waalee H, et al. Neural function during emotion regulation and future depressive symptoms in youth at risk for affective disorders. Neuropsychopharmacology. 2021;46(7):1340-7.
51. Legrum S. Adult adhd comorbidity with posttraumatic stress disorder and acute reaction to stress: Vilniaus universitetas.; 2025.
52. Cardoner N, Andero R, Cano M, Marin-Blasco I, Porta-Casteràs D, Serra-Blasco M, et al. Impact of Stress on Brain Morphology: Insights into Structural Biomarkers of Stress-related Disorders. Curr Neuropharmacol. 2024;22(5):935-62.
53. Zhou Y, Wei L, Gao S, Wang J, Hu Z. Characterization of diffusion magnetic resonance imaging revealing relationships between white matter disconnection and behavioral disturbances in mild cognitive impairment: a systematic review. Frontiers in neuroscience. 2023;17:1209378.
54. Singh SB, Tiwari A, Katta MR, Kafle R, Ayubcha C, Patel KH, et al. The utility of PET imaging in depression. Front Psychiatry. 2024;15:1322118.
55. Goes FS. Diagnosis and management of bipolar disorders. Bmj. 2023;381:e073591.
56. Liu RT, Walsh RFL, Sheehan AE, Cheek SM, Sanzari CM. Prevalence and Correlates of Suicide and Nonsuicidal Self-injury in Children: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022;79(7):718-26.
57. Kaur R, Kaur R. Symptoms, risk factors, diagnosis and treatment of urinary tract infections. Postgrad Med J. 2021;97(1154):803-12.
58. Niu M, Zhang Y, Zhang X, Yangyang C, Zhuang X, Li J, et al. Dissection of the clinical phenome of major depressive disorder into subdomains and subgroups in relation to activated immune-inflammatory profiles. medRxiv. 2025:2025.10. 21.25338439.
59. Platona RI, Căiţă GA, Voiţă-Mekeres F, Peia AO, Enătescu RV. The impact of psychiatric comorbidities associated with depression: a literature review. Med Pharm Rep. 2024;97(2):143-8.
60. Marx W, Penninx BW, Solmi M, Furukawa TA, Firth J, Carvalho AF, et al. Major depressive disorder. Nature Reviews Disease Primers. 2023;9(1):44.
61. Rolin D, Whelan J, Montano CB. Is it depression or is it bipolar depression? J Am Assoc Nurse Pract. 2020;32(10):703-13.
62. Senaratne H, Oviatt S, Ellis K, Melvin G. A critical review of multimodal-multisensor analytics for anxiety assessment. ACM Transactions on Computing for Healthcare. 2022;3(4):1-42.
63. Berk M, Köhler−Forsberg O, Turner M, Penninx BW, Wrobel A, Firth J, et al. Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management. World psychiatry. 2023;22(3):366-87.
64. Appleton HD. An Exploration of the Presence and Behavioural Manifestation of Anxiety in Children and Young Adults with Autism Spectrum Disorder and Intellectual Disability. 2022.
65. Karrouri R, Hammani Z, Benjelloun R, Otheman Y. Major depressive disorder: Validated treatments and future challenges. World journal of clinical cases. 2021;9(31):9350.
66. Gao K, Oruc EB, Koparal B. Pharmacological Monotherapy for Depressive Disorders: Current and Future-A Narrative Review. Medicina (Kaunas). 2025;61(4).

ISSN: 3093-4737

67. Miguel C, Karyotaki E, Ciharova M, Cristea IA, Penninx B, Cuijpers P. Psychotherapy for comorbid depression and somatic disorders: a systematic review and meta-analysis. Psychol Med. 2023;53(6):2503-13.
68. Sejbuk M, Mirończuk-Chodakowska I, Witkowska AM. Sleep quality: a narrative review on nutrition, stimulants, and physical activity as important factors. Nutrients. 2022;14(9):1912.
69. Shafique H, Demers JC, Biesiada J, Golani LK, Cerne R, Smith JL, et al. (R)-(-)-ketamine: the promise of a novel treatment for psychiatric and neurological disorders. International journal of molecular sciences. 2024;25(12):6804.
70. Monaco F, Vignapiano A, Piacente M, Farina F, Pagano C, Marenna A, et al. Innova4Health: an integrated approach for prevention of recurrence and personalized treatment of Major Depressive Disorder. Frontiers in artificial intelligence. 2024;7:1366055.
71. Chang JP-C, Zamparelli A, Nettis M, Pariante C. Antidepressant drugs: mechanisms of action and side effects. Encyclopedia of Behavioral Neuroscience. 2022;1:V1-613.
72. Zhou Y, Zhao D, Zhu X, Liu L, Meng M, Shao X, et al. Psychological interventions for the prevention of depression relapse: systematic review and network meta-analysis. Transl Psychiatry. 2023;13(1):300.
73. Ruiz A, Haseeb A, Baumgartner W, Lueng E, Scaini G, De Quevedo JL. New insights into the mechanisms of electroconvulsive therapy in treatment-resistant depression. Frontiers in psychiatry. 2025;16:1614076.
74. Adadzi J, Kerna NA. Optimizing Major Depression Management by Integrating Physical Activity and Targeted Lifestyle Changes. Authorea Preprints. 2024.
75. Halaris A, Cook J. The glutamatergic system in treatment-resistant depression and comparative effectiveness of ketamine and esketamine: role of inflammation? Neuroinflammation, Gut-Brain Axis and Immunity in Neuropsychiatric Disorders: Springer; 2023. p. 487-512.
76. Ibrahim MMA. The role of psychotherapy and pharmacotherapy in managing major depressive disorder. Int J Psychol Sci. 2025;7(1):18-27.
77. Van den Eynde V, Abdelmoemin WR, Abraham MM, Amsterdam JD, Anderson IM, Andrade C, et al. The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression. CNS spectrums. 2023;28(4):427-40.
78. Dagher M. Investigating Changes in Monoamine Transmission Induced by Stress: University of California, Los Angeles; 2022.
79. Qi X. Neuropharmacology of Neurotransmitter Systems: Current Drugs and Their Effects on Neural and Neuroendocrine Pathways. Asia Pacific Journal of Clinical Medical Research. 2025;1(1).
80. Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee HC, et al. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood cancer journal. 2021;11(2):40.
81. Lin J, Liu W, Guan J, Cui J, Shi R, Wang L, et al. Latest updates on the serotonergic system in depression and anxiety. Frontiers in Synaptic Neuroscience. 2023;15:1124112.

ISSN: 3093-4737

82. Mazreno B, Taghian A. F.(2023). Fatigue in Aging: The Influence of Serotonin and Potential Therapeutic Strategies. Journal of Humanistic approach to sport and exercise studies (HASES).3(3):512-22.
83. Edinoff AN, Swinford CR, Odisho AS, Burroughs CR, Stark CW, Raslan WA, et al. Clinically relevant drug interactions with monoamine oxidase inhibitors. Health psychology research. 2022;10(4):39576.
84. Bar-Kalifa E, Bringmann LF, Zilcha-Mano S. The role of affect dynamics as mechanisms of change in mental health interventions: Integrating applied and basic science. Journal of Consulting and Clinical Psychology. 2024;92(8):445.
85. Salkovskis PM, Sighvatsson MB, Sigurdsson JF. How effective psychological treatments work: mechanisms of change in cognitive behavioural therapy and beyond. Behavioural and cognitive psychotherapy. 2023;51(6):595-615.
86. Zhang X. Effects of Posttraumatic Cognitions, Working Alliance, and Relational Intimacy Skills in PTSD Treatment: Marquette University; 2024.
87. Oberoi T. Common Mechanisms of Change in Mindfulness-Based Cognitive Therapy (MBCT) and Traditional Cognitive Behavioral Therapy (CBT): Implications for Therapeutic Effectiveness. The National High School Journal of Science; 2024.
88. Wang X, Feng Z. A narrative review of empirical literature of behavioral activation treatment for depression. Frontiers in Psychiatry. 2022;13:845138.
89. Burback L, Brult-Phillips S, Nijdam MJ, McFarlane A, Vermetten E. Treatment of posttraumatic stress disorder: a state-of-the-art review. Current neuropharmacology. 2024;22(4):557-635.
90. Xie Y, Wu Z, Sun L, Zhou L, Wang G, Xiao L, et al. The effects and mechanisms of exercise on the treatment of depression. Frontiers in psychiatry. 2021;12:705559.
91. Naragatti S. The Role of Yoga in Balancing Hormones: A Comprehensive Research Review. International Journal For Multidisciplinary Research. 2025;7(1):1-12.
92. Lu EY, Cheng AS, Tsang HW, Chen J, Leung S, Yip A, et al. Psychoeducation, motivational interviewing, cognitive remediation training, and/or social skills training in combination for psychosocial functioning of patients with schizophrenia spectrum disorders: A systematic review and meta-analysis of randomized controlled trials. Frontiers in psychiatry. 2022;13:899840.
93. Antos Z, Żukow X, Bursztynowicz L, Jakubów P. Beyond NMDA Receptors: A Narrative Review of Ketamine's Rapid and Multifaceted Mechanisms in Depression Treatment. International Journal of Molecular Sciences. 2024;25(24):13658.
94. Bhatt S, Devadoss T, Jha NK, Baidya M, Gupta G, Chellappan DK, et al. Targeting inflammation: a potential approach for the treatment of depression. Metabolic Brain Disease. 2023;38(1):45-59.
95. Jain N, Nagaich U, Pandey M, Chellappan DK, Dua K. Predictive genomic tools in disease stratification and targeted prevention: a recent update in personalized therapy advancements. EPMA Journal. 2022;13(4):561-80.
96. Scangos KW, State MW, Miller AH, Baker JT, Williams LM. New and emerging approaches to treat psychiatric disorders. Nature medicine. 2023;29(2):317-33.

ISSN: 3093-4737

97. Rymaszewska J, Wieczorek T, Fila-Witecka K, Smarzewska K, Weiser A, Piotrowski P, et al. Various neuromodulation methods including Deep Brain Stimulation of the medial forebrain bundle combined with psychopharmacotherapy of treatment-resistant depression—Case report. Frontiers in Psychiatry. 2023;13:1068054.
98. Chen X, Zhang T, Shan X, Yang Q, Zhang P, Zhu H, et al. High-frequency repetitive transcranial magnetic stimulation alleviates the cognitive side effects of electroconvulsive therapy in major depression. Frontiers in Psychiatry. 2022;Volume 13 - 2022.
99. Korai SA, Ranieri F, Di Lazzaro V, Papa M, Cirillo G. Neurobiological after-effects of low intensity transcranial electric stimulation of the human nervous system: from basic mechanisms to metaplasticity. Frontiers in Neurology. 2021;12:587771.
100. Naik A, Chu T, Gupta R, Saadah B, Gangidi S, Lee C, et al. Deep brain stimulation for treatment-resistant major depressive disorder: a network meta-analysis of stimulation targets. J Neurosurg. 2025:1-10.
101. Deif R, Salama M. Depression from a precision mental health perspective: utilizing personalized conceptualizations to guide personalized treatments. Frontiers in psychiatry. 2021;12:650318.
102. Campos AI, Mulcahy A, Thorp JG, Wray NR, Byrne EM, Lind PA, et al. Understanding genetic risk factors for common side effects of antidepressant medications. Communications medicine. 2021;1(1):45.
103. Jani J, Lin CLS, Mudin DKD, Muniandy RK. Bridging the genetic gulf: a deep dive into neurotransmission, pharmacogenomics, and genetic variations for optimal pain management. Neuroscience Research Notes. 2024;7(2):316.1-.15.
104. Kobeissy F, Goli M, Yadikar H, Shakkour Z, Kurup M, Haidar MA, et al. Advances in neuroproteomics for neurotrauma: unraveling insights for personalized medicine and future prospects. Frontiers in neurology. 2023;14:1288740.
105. Asghar S, Virk MKS, Taskeen B, Fatima M, Wandala A. The role of pharmacogenomics in Advancing Personalised Medicine: Implications for Drug Efficacy Safety and clinical practice Integration. Indus Journal of Bioscience Research. 2025;3(5):637-45.
106. Jadhav OP, Choure V. TELEMEDICINE: TRANSFORMING HEALTHCARE DELIVERY IN THE DIGITAL AGE. Int J Acad Med Pharm. 2024;6(3):565-71.
107. Cogiel K, Sawina A, Guzowska A, Lau K, Kasperczyk J. Managing chronic disease in the digital era: The role of telemedicine apps and platforms. Przegl Epidemiol. 2025;79(1):83-94.
108. Shahzadi N. Improving Access to Healthcare for Rural Populations: Strategies and Solutions. Multidisciplinary Journal of Healthcare (MJH). 2024;1(1):42-52.
109. Grande D, Marti XL, Feuerstein-Simon R, Merchant RM, Asch DA, Lewson A, et al. Health policy and privacy challenges associated with digital technology. JAMA network open. 2020;3(7):e208285-e.
110. Watanabe TK, Esquenazi A, Flanagan S. The transformation of the rehabilitation paradigm across the continuum of care. PM&R. 2018;10(9):S264-S71.
111. Killaspy H. Contemporary Mental Health Rehabilitation: Keeping it Simple in a Complex World. World Social Psychiatry. 2023;5(1):51-4.

ISSN: 3093-4737

112. Morris ME, Perry A, Bilney B, Curran A, Dodd K, Wittwer JE, et al. Outcomes of physical therapy, speech pathology, and occupational therapy for people with motor neuron disease: a systematic review. Neurorehabilitation and neural repair. 2006;20(3):424-34.
113. Jeschke MG, van Baar ME, Choudhry MA, Chung KK, Gibran NS, Logsetty S. Burn injury. Nature reviews Disease primers. 2020;6(1):11.
114. Safran DG, Graham JD, Osberg JS. Social supports as a determinant of community-based care utilization among rehabilitation patients. Health Services Research. 1994;28(6):729.
115. Besemann LM, Hebert J, Thompson JM, Cooper RA, Gupta G, Brémault-Phillips S, et al. Reflections on recovery, rehabilitation and reintegration of injured service members and veterans from a bio-psychosocial-spiritual perspective. Canadian Journal of Surgery. 2018;61(6 Suppl 1):S219.
116. Tol WA, Barbui C, Galappatti A, Silove D, Betancourt TS, Souza R, et al. Mental health and psychosocial support in humanitarian settings: linking practice and research. The Lancet. 2011;378(9802):1581-91.
117. Smit D, Miguel C, Vrijsen JN, Groeneweg B, Spijker J, Cuijpers P. The effectiveness of peer support for individuals with mental illness: systematic review and meta-analysis. Psychol Med. 2023;53(11):5332-41.
118. DeLancey JOL, Masteling M, Pipitone F, LaCross J, Mastrovito S, Ashton-Miller JA. Pelvic floor injury during vaginal birth is life-altering and preventable: what can we do about it? Am J Obstet Gynecol. 2024;230(3):279-94.e2.
119. Downing J, Sjeklocha L. Trauma in Pregnancy. Emerg Med Clin North Am. 2023;41(2):223-45.
120. Sylaska KM, Edwards KM. Disclosure of intimate partner violence to informal social support network members: A review of the literature. Trauma, violence, & abuse. 2014;15(1):3-21.
121. Kendall E, Catalano T, Kuipers P, Posner N, Buys N, Charker J. Recovery following stroke: the role of self-management education. Social science & medicine. 2007;64(3):735-46.
122. Sano Y, Mammen S, Houghten M. Well-being and stability among low-income families: A 10-year review of research. Journal of Family and Economic Issues. 2021;42(Suppl 1):107-17.
123. Levasseur M, Routhier S, Clapperton I, Doré C, Gallagher F. Social participation needs of older adults living in a rural regional county municipality: Toward reducing situations of isolation and vulnerability. BMC geriatrics. 2020;20(1):456.
124. Bhaskar S, Bradley S, Chattu VK, Adisesh A, Nurtazina A, Kyrykbayeva S, et al. Telemedicine as the new outpatient clinic gone digital: position paper from the pandemic health system REsilience PROGRAM (REPROGRAM) international consortium (Part 2). Frontiers in public health. 2020;8:410.